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ABSTRACT
PURPOSE. An alternative cancer therapy based on RNA interference (RNAi) has shown considerable
promise but the possibility of resistance development is not known. This study explored the possibility
of therapeutic resistance against siRNA nanoparticles in human cancer cells. METHODS. Two
approaches to siRNA treatment were undertaken using lipid-modified polyethylenimines, a single high
concentration (shock) and repeated increasing concentrations (gradual). The targets were Mcl-1,
RPS6KA5 and KSP in MDA-MB-435 cells. RESULTS. There was no evidence of resistance
development in shock-treated cells, while the decrease in mRNA levels of targeted proteins was not as
robust in naïve cells in gradual treatment. However, silencing efficiency was restored after a 7-day
recovery period when expression of suppressed proteins returned to normal levels. Cellular uptake of
siRNA was not affected by pre-treatments. Other mediators involved in cell survival and proliferation
were altered in siRNA-treated cells, but only JUN silencing led to a heightened loss of viability. In vivo
experiments demonstrated similar silencing efficiency at mRNA level after repeat doses.
CONCLUSIONS. Human cancer cells responded to repeat siRNA nanoparticles in a similar fashion after
a temporary initial alteration and little, if any, resistance was evident against repeated siRNA treatments.
KEYWORDS: siRNA, cancer therapy, drug resistance, polymeric carriers,
LIST OF ABBREVIATIONS
FAM: Fluorescein amidite
KSP: kinesin spindle protein
Mcl-1: myeloid leukemia cell differentiation protein
mRNA: messenger RNA
NT: Non-treated
PEI-LA: linoleic acid-substituted polyethylenimine
RISC: RNA-induced silencing complex
RQ: Relative quantity
RT-PCR: real-time polymerase chain reaction
siRNA: short interfering RNA

INTRODUCTION
Innate and acquired resistance against chemotherapeutic agents is an old problem and one of major
causes of failure of cancer chemotherapy. While innate resistance is observed independent of preexposure to anticancer treatment and might be attributed to the phenotype of original malignant cells,
acquired resistance is manifested after exposure to cytotoxic agents and could result in cross-resistance
to other cytotoxic molecules with unrelated molecular structures1. Different mechanisms are involved in
acquired resistance, which include, but are not limited to: (a) reduced intracellular uptake or enhanced
efflux of drugs by membrane transporters such as P-glycoprotein and breast cancer resistance protein2,3;
(b) inhibition of apoptosis by over-expression of apoptosis inhibitors such as Mcl-14, Bcl-25,6 and
survivin7; and (c) mutations in drug target genes, which are critical for resistance against latest generation
of molecularly designed drugs, such as mutations in MEK (resistance against BRAF inhibitors)8, EGFR
(resistance against small molecule tyrosine kinase inhibitors)9, BCR-ABL (resistance against dasatinib)10
and secondary mutations in RAS proteins NRAS or KRAS (resistance against vemurafenib and
dabrafenib)11. Once the resistance sets in, it becomes necessary to employ new drugs and/or sensitizing
agents to make the malignant cells responsive to chemotherapy, which is usually not successful on the
long run.
As an alternative to drug therapy, small interfering RNA (siRNA) mediated RNA interference
(RNAi) are being intensely explored both as an investigational tool and as a therapeutic strategy12. In this
approach, expression of a target protein is “silenced” at post-transcriptional stage by intracellular delivery
of a double stranded RNA, where it is incorporated in the RNA-induced silencing complex (RISC), which
contains the Argonaute 2 enzyme that is capable of “slicing” the mRNA target. After removal of the
“passenger” strand, the remaining “guide” strand of siRNA will bind to complementary region of the
target mRNA, which triggers cleavage and subsequent degradation of the mRNA13. The siRNA on its
own is not effective due to its rapid degradation in physiological milieu and its inability to cross cell
membranes; a carrier is employed to bind and protect it from degradation and form complexes to enable

cellular uptake. It has been recognized that a large variation exists in the required siRNA copy number
for effective silencing in different cell lines with different carriers14. Based on the estimated number of
siRNA molecules delivered by a nanoparticle (e.g., 2000 copies in a 70 nm particle)15, it appears that
only a small portion of the siRNA molecules exposed to cells is available for efficient silencing. More
importantly, multiple exposures are usually required to accomplish a significant effect due to transient
nature of siRNA mediated silencing. We have little information on the effect of siRNA pre-exposure on
cellular response to subsequent siRNA treatments. While siRNA has the potential to curb tumor growth
independent of chemotherapy, it is not known if it is susceptible to resistance development similar to
conventional drugs. Should we expect appearance of cell populations that do not respond to siRNA
silencing due to previous exposure? Can internalization of siRNA complexes be minimized as a result of
siRNA pre-exposure, reminiscent of induction of efflux proteins (e.g., ABC membrane proteins) that
minimize cellular accumulation of cytotoxic drugs? In the only study reported on the possibility of siRNA
resistance, cellular adaptation was found to contribute to resistance to viruses; siRNA efficacy was
inhibited by adenosine deaminases acting on RNA, which ‘edits’ the delivered siRNA by converting
adenosine-to-inosine (A-to-I)16. Considering these unresolved issues, a more in depth investigation of
cellular responses to repeat siRNA treatments is warranted.
This study was designed to investigate the effect of siRNA pre-exposure on subsequent response
of a human cancer model (MDA-MB-435 cells) to siRNA therapy. A systematic approach was
undertaken to investigate this issue by using two siRNA exposure methods. The pre-exposure to siRNA
was performed either by a single, high concentration of siRNA treatment or by multiple treatments with
gradually increasing siRNA concentrations, which will be referred to as “shock” and “gradual”
treatments, respectively. We selected three siRNAs that were previously shown to be effective in
retarding growth in the chosen cell model: (i) an siRNA targeting myeloid cell leukemia 1 (Mcl-1)
protein, (ii) an siRNA targeting kinesin spindle protein (KSP), and; (iii) a combination of siRNAs
targeting Mcl-1 and RPS6KA5 proteins, whose efficacy was identified from a library screen of siRNA

combinations17. The effect of siRNA pre-exposure on MDA-435 cells was evaluated by investigating
cellular internalization of siRNA, expression levels of targeted proteins at the mRNA level, and the
resultant cellular viabilities. The cells were monitored during the siRNA treatments, as well as after a
given period to analyze the cellular recovery after the siRNA therapy. An animal model was subsequently
employed to confirm our findings in vivo.

MATERIAL AND METHODS
Materials. The 2 kilo Dalton (kDa) PEI (PEI2; Mn: 1.8 kDa, Mw: 2 kDa), anhydrous dimethylsulfoxide
(DMSO), linoleyl chloride (C18:2 9Z,12Z; 99%), Hanks’ Balanced Salt Solution (HBSS; with phenol
red), trypsin/EDTA, and 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT)
were purchased from SIGMA (St. Louis, MO). Clear HBSS (phenol red-free) was obtained from Lonza
Inc. (Allendale, NJ). RPMI 1640 medium, penicillin (10000 U/mL) and streptomycin (10 mg/mL), Taq
DNA polymerase, M-MLV reverse transcriptase, and RNaseOUT ribonuclease inhibitor were provided
by Invitrogen (part of Life Technologies, Grand Island, NY). Fetal bovine serum (FBS) was from PAA
Laboratories (Etobicoke, Ontario). RDD buffer were purchased from Qiagen (Mississauga, ON). Trizol®
reagent was provided by Ambion (Burlington, Ontario).

Cell Line. MDA-MB-435 (MDA-435) cells were a generous gift from Dr. Robert Clarke (Georgetown
University, Washington, DC). The cells were cultured in RPMI 1640 medium supplemented with 10%
FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin at 37°C and 5% CO2. Cell cultures were
considered confluent when a cell monolayer covered more than 80% of the flask surface (equivalent to
600,000 – 900,000 cells/mL; approximately equivalent to 100,000 cells/cm2). To propagate the cells, the
monolayer was washed with HBSS and treated with 0.05% Trypsin/EDTA at room temperature. The

suspended cells were centrifuged at 600 rpm for 5 minutes, re-suspended in fresh medium, and subcultured at 10% of the original count.

siRNAs and Primers. The scrambled siRNA (catalogue no: AM4635; used as negative control),
Fluorescein amidite (FAM)-labeled scrambled siRNA (catalogue no: AM4620; used in uptake studies),
and the siRNAs targeting KSP (catalogue no: AM16704; Ambion Silencer®, unmodified) and ribosomal
protein S6 kinase, polypeptide 5 (RPS6KA5; Catalogue number: AM51334; Ambion Silencer®,
unmodified) were provided by Ambion (Burlington, Ontario). The siRNA against induced myeloid
leukemia cell differentiation protein (Mcl-1; catalogue no: SI02781205; Flexitube® siRNA) was supplied
by Qiagen (Mississauga, ON). The primers used for the RT-PCR reactions were designed using the
Primer-Blast software available at The National Center for Biotechnology Information website
(http://www.ncbi.nlm.nih.gov/) and were synthesized with the following sequences by the IDT
Technologies (Coralville, Iowa), before being validated in house:
β-actin (as endogenous protein):
eIF4:
FOS:
JAK2:
JUN:
KSP:
Mcl-1:
MYC:
NFƙB:
RPS6KA5:

Forward: 5’-CCA CCC CAC TTC TCT CTA AGG A-3’
Reverse: 5’-AAT TTA CAC GAA AGC AAT GCT-3’
Forward: 5’-GAG GAC GAT GGC TAA TTA CAT TGA-3’
Reverse: 5’-GCA CAG AAG TGT CTC TAG CCA AAA-3’
Forward: 5’-CTG AAG ACC GAG CCC TTT GA-3’
Reverse: 5’-GGA GCG GGC TGT CTC AGA-3’
Forward: 5’-AAC TGC AGA TGC ACA TCA TTA CCT-3’
Reverse: 5’-TCG AAA TTG GGC CAT GAC A-3’
Forward: 5’-GAG AGG AAG CGC ATG AGG AA-3’
Reverse: 5’-TCC AGC CGG GCG ATT-3’
Forward: 5’-TCA CAA AAG CAA TGT GGA AAC CTA-3’
Reverse: 5’-TCT GTC CAA AGA TTCA TTA ACT TGC A-3’
Forward: 5’-CCT TTG TGG CTA AAC ACT TGA AG-3’
Reverse: 5’-CGA GAA CGT CTG TGA TAC TTT CTG-3’
Forward: 5’-TGG TCT TCC CCT ACC CTC TCA-3’
Reverse: 5’-AGA ATC CGA GGA CGG AGA GAA-3’
Forward: 5’-AAT GGG CTA CAC CGA AGC AA-3’
Reverse: 5’-CAG CGA GTG GGC CTG AGA-3’
Forward: 5’-GAC ACT GCA GCC CAG CAA-3’
Reverse: 5’-CCT AAG CTA CTG AGT CCG AGA ACT G-3’

S6K:
STAT3:
Survivin:

Forward: 5’-AAT CCG ATC ACC TCG AAG ATT TAT-3’
Reverse: 5’-CTG TGC TGG CCG AAG CA-3’
Forward: 5’-ACA ACA TGT CAT TTG CTG AAA TCA-3’
Reverse: 5’-TCC TTG GGA ATG TCA GGA TAG AG-3’
Forward: 5’-CCC CTC GGG CCA ACT G-3’
Reverse: 5’-CAG TTT GGC TTG CTG GTC TCT-3’

Preparation of siRNA Complexes. Lipid modification method to functionalize 2 kDa PEI for siRNA
delivery was previously described18,19. For this study siRNA complexes were formed by mixing selected
siRNA(s) with a linoleic acid-substituted PEI (PEI-LA; 2.1 LA/PEI) at a polymer:siRNA weight/weight
ratio of 8:1. Detailed complex formation procedure and characterization of these complexes, as well as
silencing model (GFP) and endogenous proteins, have been reported previously20.

Pre-exposure to siRNA. The cells underwent siRNA treatment by using two distinct approaches: (1)
Shock method: The MDA-435 cells were seeded in 6-well plates at 20% confluency. After 24 hours
incubation at 37 °C, cells were treated with a relatively high dose of siRNA with the final concentration
of 54 nM in culture medium. Surviving cells were collected by trpsinization after 72 hours of siRNA
exposure and were transferred to a cell culture flask to recover or for specific experiments. (2) Gradual
method: Cells were seeded under the same conditions as the “shock” method; however, the exposure to
siRNA was performed with gradually increasing concentrations of 9, 18, and 27 nM, with a final
concentration of 27 nM as a repeat treatment. The cells were collected after 72 h exposure to each
concentration and seeded in a new plate (at 20% confluency) for the next treatment. After the second
27 nM exposure, surviving cells were collected and transferred to a cell culture flask to recover. The preexposure procedures are summarized in Supplementary Figure 1.

Cellular Internalization of siRNA. The effect of pre-exposure to siRNA on subsequent cellular
internalization was evaluated in naïve cells and cells exposed to siRNA by “shock” and “gradual”
methods. The desired cells were seeded in 24-well plates at 50% confluency, and incubated at 37 °C
for 24 h. Cells were then exposed to the complexes prepared with PEI-LA/FAM-labeled scrambled
siRNA or non-labeled scrambled siRNA (as negative control) with a polymer:siRNA ratio of 8:1 and
final siRNA concentration of 18 nM. After 24 h incubation, cells were washed with clear HBSS and
suspended in clear trypsin before being fixed in a 3.7% formaldehyde solution. A Beckman Coulter
QUANTA SC flow cytometer was used to quantify the average uptake and the siRNA-positive
population. The FL1 channel of the flow cytometer was used to quantify the cell-associated FAM
fluorescence. A “No Treatment (NT)” group was added to each set of experiment to gate the analysis
and ensure that the auto-fluorescent cell population represented only 1-2% of the total cell population.
Laser Scanning Confocal Microscope was also used for visual inspection of internalized siRNA
complexes. Naïve and siRNA pre-exposed cells were seeded in 6-well plates containing glass slides in
each well. After exposure to complexes formed with PEI-LA and FAM-labeled or non-labeled siRNA
(30 nM siRNA concentration) for 24 or 72 h, cells were washed with clear HBSS and fixed in a 3.7%
formaldehyde solution for 30 minutes in room temperature. The fixed cells were then washed with HBSS
before being stained with a 1 μg/mL solution of tetramethylrhodamine wheat germ agglutinin (WGA)
conjugate that selectively binds to N-acetylglucosamine and N-acetylneuraminic acid residues in cell
membrane21. After 2 minutes incubation with the dye at 37 °C, cells were washed with HBSS twice, and
the glass slide was mounted with a medium (polyvinyl alcohol in glycerol) containing 1 μg/mL 4',6diamidino-2-phenylindole (DAPI; Life Technologies, Grand Island, NY). Prepared slides were studied
with a Zeiss LSM710 LSCM.

Real-time Polymerase Chain Reaction (RT-PCR). The efficiency of siRNA silencing in naïve and
siRNA pre-exposed cells was investigated at the mRNA level using RT-PCR. Cellular RNA was
extracted by the Trizol® protocol. Briefly, cells were lysed with Trizol (1 mL for each 1 × 106 cells) and
incubated at room temperature for 5 minutes. Chloroform (0.2 mL for each mL of Trizol) was added to
lysed samples, and after vigorous shaking and 2-3 minutes incubation at room temperature, the aqueous
phase was separated. RNA was then precipitated with isopropanol and the pellet was washed with 75%
ethanol. Extracted RNA was dissolved in RNAse free water, and the total RNA was determined by
Nanodrop Lite (Thermo Fisher Scientific, Wilmington, DE). RNA (0.5 μg) was reverse transcribed to
synthesize cDNA by using random hexamer primer and dNTP mix at 65 °C for 5 min. Synthesis buffer
(5×), DTT (0.1 M), and RNAout RNase inhibitor (1.8 U/μL) were then added and the solution was
incubated at 37 °C for 2 min. MMLV RT enzyme was added and samples were incubated at 25 °C for
10 min, 37 °C for 50 min, and 70 °C for 15 min. An ABI 7500 HT instrument (Applied Biosystems, now
part of Life Technologies, Grand Island, NY) was used for RT-PCR analysis using human β-actin as the
endogenous gene. All the primers were tested to assure equal efficiency (with a slope ˂ 0.1 for the ΔCT
vs. cDNA dilution graph for different primers designed for each protein of interest), and a template
concentration of 10 ng/μL was determined as the optimal concentration based on the standard curves.
Analysis was performed by calculating ΔCT, ΔΔCT, and relative quantity (RQ) using endogenous gene
and “no treatment” group as reference points.

Evaluation of Cell Viability after siRNA Treatment. The effect of siRNA silencing on the number of
viable cells was evaluated during and after each exposure by a standard MTT assay as reported
previously20. The cells were exposed to indicated siRNA complexes for 72 h before the assay, and the
MTT assay was performed during the stages of gradual treatment method, after completion of both
exposure methods (using different siRNA concentrations selected based on the efficacy of each
treatment).

Animal Studies. All experiments were performed according to the University of Alberta guidelines for
the care and use of laboratory animals. 4-6 weeks old female NCR nu/nu nude mice (Taconic Farms)
were kept in a bio containment unit for at least one week and then ~2 million MDA435WT were
subcutaneously injected into the right flank of the mice. Tumor growth was monitored every 72-96 hours
by volume measurements that were performed by a digital caliper. Animals were included in the study
when developed a tumor of 50-100 mm3 (length × width2 × 0.4). Tumor-bearing animals were randomly
assigned to two different treatment groups: animals treated with scrambled siRNA (CsiRNA) and animals
treated with Mcl-1/RPS6KA5. Complexes were prepared with a PEI-LA2.1:siRNA w/w ratio of 8:1 and
each animal received 1.5 μg of each siRNA/mouse (~ 0.06 mg/kg/day; 3 μg or 0.12 mg/kg/day total for
CsiRNA group) via subcutaneous injections by the tumor site. Injections were administered at 7-days
intervals (to allow recovery from the silencing effect of injections) for a total of three injections. A total
of 18 mice were assigned to each group, and they were euthanized as followed:
3 mice: 72 hours after 1st injection (to analyze the silencing efficiency by PCR)
3 mice: 7 days after 1st injection (to evaluate recovery of targets and as baseline for second injection)
3 mice: 72 hours after 2nd injection (to analyze the efficiency of repeated silencing by PCR)
3 mice: 7 days after 2nd injection (to evaluate recovery of targets and as baseline for third injection)
3 mice: 72 hours after 3rd injection (to analyze the efficiency of repeated silencing by PCR)
At the end of treatment period, tumors were extracted and stored in RNAlater® in -20°C. Tumor samples
were homogenized for RNA extraction and q-PCR analysis.

Statistical Analysis
The significance of the changes in siRNA cellular internalization (calculated both as mean
fluorescence and percentage of cells positive for labeled siRNA), mRNA levels (analyzed by RT-PCR),
and cell viability were evaluated using Student’s t-test (p<0.05). Standard deviations were calculated for
all results shown and are represented as the error bar in all figures.

RESULTS
Shock siRNA Treatment
In order to confirm the initial responsiveness of MDA-435 cells to selected siRNAs, cells were
exposed to 54 nM of scrambled, Mcl-1, Mcl-1/RPS6KA5, and KSP siRNAs for 72 hours, and obtained
cell viabilities are summarized in Figure 1a. While the negative control (scrambled siRNA) showed a
more significant response than expected at the chosen concentration (54 nM), a greater decrease in cell
viability was observed for all selected siRNAs, with a significant additive effect for the combination of
Mcl-1 and RPS6KA5 siRNAs as reported before17. After the recovery (7 days after the treatment), the
cells were treated with selected siRNAs again using a range of concentrations (9 – 54 nM). The response
of the pre-treated and the naïve cells to scrambled siRNA, as well as Mcl-1, and KSP siRNAs showed a
similar pattern (Figure 1b), with a slight decrease in the level of response to 18 nM siRNA targeting
KSP in the pre-treated cells compared to naïve cells, which disappeared at the higher dose of 27 nM. The
decrease in the viability with Mcl-1/RPS6KA5 siRNA combination was significantly lower in cells
previously exposed to the same combination at 54 nM compared to naïve cells (90.8 ± 5.5% vs. 73.9 ±
12.0% for 18 nM siRNA and 64.7 ± 4.5% vs. 28.1 ± 6.7% for 27 nM siRNA, respectively).
In order to evaluate changes in the expression level of selected proteins, RT-PCR analysis was
performed after 24 and 72 hours of shock siRNA treatment. The 24-hour time point represented the initial
response to siRNA exposure while the 72-hour time point represented mRNA levels in surviving cells.
After 24 hours, significant decreases in mRNA level of targeted proteins (86% decrease in Mcl-1
mRNA for both Mcl-1 and Mcl-1/RPS6KA5 treated cells, ~86% decrease for RPS6KA5 mRNA for
combinational treated cells, and ~93% decrease in KSP mRNA in cells treated with KSP siRNA) were
observed in all treatment groups (Figure 1c). It is noteworthy that the scrambled siRNA also showed a
significant decrease in mRNA level of all monitored proteins, which was most significant for KSP (50%

of the “no treatment” expression level). However, there was a greater decrease in the mRNA levels for
cells treated with specific siRNAs. The expression levels of all selected proteins were significantly higher
after 72 hours (vs. 24 hours) in cells exposed to scrambled siRNA. In fact, this expression levels were
even higher than the naïve cells, which was more significant for Mcl-1 and KSP. In specific siRNA
treated cells, the mRNA levels were also higher than the levels at the 24-hour time point, but not as high
as the mRNA levels in naïve cells. The RT-PCR analysis was repeated after 7 and 14 days for naïve and
treated cells to explore changes in mRNA levels after recovery. After 7 days (Figure 1d), mRNA levels
for the selected proteins showed a significant increase over the initial response. However, the mRNA
levels of specifically targeted proteins were still lower than the naïve cells. After 14 days (Figure 1e),
the mRNA levels of targeted proteins returned to initial levels (i.e., equivalent to naïve cells). Finally,
the repeat siRNA silencing (with 54 nM siRNA) after 7 days of initial treatment showed a similar
responsiveness in naïve and shock-treated cells (Figure 1f). However, the effect of scrambled siRNA
was not always similar in naïve and recovered cells: while the mRNA level of Mcl-1 showed a more
significant decrease in recovered, scrambled siRNA treated cells, KSP mRNA levels was significantly
lower in naïve cells.
Cellular internalization of FAM-siRNA particles was analyzed using confocal microscopy at two
time points (24 and 72 hours after treatment), as well as flow cytometry after 24 hours exposure. The
mean fluorescence and percentage of FAM-siRNA positive cells were negligible for particles formed
with non-labeled siRNA, as expected. Significant uptake was evident for cells exposed to FAM-siRNA
complexes in naïve and shock treated cells (Figures 2a and 2b, respectively). The siRNA uptake in cells
previously exposed to Mcl-1/RPS6KA5 and KSP siRNAs was significantly lower than the naïve cells.
Confocal microscopy analysis after 24 hours revealed a similar uptake pattern that showed the complexes
inside the cytoplasm, but a non-homogenous uptake pattern among the cells, with some cells showing
>10 particles internalized, while other cells seemed particle-free (Figure 2c). At 72 hours after treatment,

most internalized particles disappeared, with few particles remaining in all cells and no obvious
differences among the study groups.

Gradual siRNA Treatment
The cells were monitored for their responsiveness to gradually increasing siRNA after each
treatment. Figure 3a summarizes the response of the naïve cells as well as cells treated with specific
siRNAs (exposure to 18 and 27 nM siRNA after exposure to 9 and 18 nM siRNA concentrations,
respectively), where cell viability was compared to “No Treatment” group. Pre-exposure to a lower
concentration of siRNA did not seem to affect the subsequent cell response, where similar pattern of cell
viability was observed as the result of exposure to higher siRNA concentration in the next treatment. A
similar experiment (with a wider range of siRNA concentrations) was performed 7 days after the
completion of gradual exposures (Figure 3b). For cells exposed to scrambled or Mcl-1 siRNA, the
response was similar to naïve cells, with the exception of the response at 54 nM scrambled siRNA (where
cells pre-exposed to scrambled siRNA showed a lower response compared to naïve cells) and 27 nM
Mcl-1 siRNA (where a similar difference was observed). For Mcl-1/RP6KA5 siRNA combination or
KSP siRNA, pre-exposed cells showed lower response compared to naïve cells, especially at higher
concentrations of siRNA.
The silencing efficiency was also evaluated at the mRNA level after 24 and 72 hours of each
exposure (Figure 4). For the first exposures (9 nM siRNA) representing the initial response of naïve
cells, the decrease in mRNA level was minimal after 24 hours, where a significant difference was
observed only for the Mcl-1/RPS6KA5 and KSP treatment groups. This difference disappeared after 72
hours, and in fact, a higher level of mRNA was observed in both scrambled and KSP siRNA treated cells.
For the second exposures (18 nM siRNA), a significant drop in mRNA levels for all targeted proteins
was observed (but not with scrambled siRNA) after 24 hours of exposure; however, the level of response
was significantly lower in cells pre-exposed to Mcl-1 and RPS6KA5 siRNAs. This difference was not

significant for KSP treatment. A similar trend was observed after 72 hours for cells co-treated with Mcl1 and RPS6KA5 siRNAs. The 72-hour KSP mRNA level in cells pre-exposed to 9 nM of KSP siRNA
was significantly higher than the corresponding group at the earlier time point. A similar trend was not
observed after the third stage of exposure (27 nM siRNA), but re-appeared after the second exposure to
27 nM siRNA (the last stage of gradually increasing siRNA exposures). On the other hand, after a
significant improvement in silencing with increasing siRNA concentration from 9 to 18 nM, the second
increase in siRNA concentration (from 18 to 27 nM) did not yield a similar increase in silencing in naïve
or pre-treated cells.
The RT-PCR analysis was repeated after 7 and 14 days of the last siRNA treatment (Figure 5).
The recovery process was slower for the gradual siRNA treatment, where the levels of targeted mRNAs
after 7 days (except KSP) was lower than the corresponding time point in the shock treatment (Figure
5a; compare to Figure 1d). This difference, however, disappeared after 14 days (Figure 5b), where the
mRNA levels returned to similar levels as the naïve cells. Similar to the shock-treated cells, a repeat
silencing with high siRNA concentration (54 nM) after 7 days of completion of gradual exposures
showed no significant difference in mRNA levels of naïve and pre-treated cells (Figure 5c).
The flow cytometry results for siRNA uptake in naïve and cells treated with gradual siRNA
exposures are summarized in Figures 6a and 6b; no negative impact on cellular uptake of
polymer/siRNA particles was observed as a result of previous siRNA treatment. In fact, the mean
fluorescence in cells pre-exposed to gradual siRNA against KSP was even higher than the naïve cells
(Figure 6b). No significant difference was observed in the percentage of FAM-siRNA positive cells for
pre-treated cells compared to the naïve cells. The confocal microscopy evaluations revealed a similar
cellular internalization to our observations with cells pre-treated with the “shock” method; while
significant (but non-homogeneous) uptake was apparent after 24 hours, particles seemed to dissociate
after 72 hours, where few fluorescent particles was observed in selected cell populations.

Targeting Related Proteins in siRNA-Treated Cells
To investigate the effect of siRNA treatments on expression of other proteins potentially involved
in cell survival, mRNA levels of a select group of proteins were analyzed 24 and 72 hours after the shock
treatment and the last step in gradual exposures to Mcl-1 and Mcl-1/RPS6KA5 siRNAs. The initial (24
hours) response to shock treatment was a reduction of the targeted proteins (as expected), as well as a
reduction in mRNA levels of survivin (both treatment groups), JAK2, eIF4, and NFƙB (more significant
in Mcl-1/RPS6KA5 combination group), MYC, S6K, and STAT3 (only in Mcl-1/RPS6KA5 combination
group) (Figure 7a). For cells gradually exposed to siRNA, on the other hand, a reduction could only be
observed in survivin mRNA, while several proteins (JUK, NFƙB and MYC in particular) showed an
overexpression as a result of multiple exposures over time (Figure 7b). At 72 hours, a reduction in
mRNA levels of targeted proteins was seen, while a significant overexpression was observed in STAT3
and JUN in both pre-exposed cell populations (Figure 7b and 7d). A significant increase in NFƙB
expression was only observed in the gradual treatment (Figure 7d).
We next treated the shock- and gradual-treated cells by specific siRNAs against significantly
altered mediators, namely JAK2, STAT3, JUN, NFƙB, MYC or S6K, and the viability of the cells was
compared to untreated MDA435 cells (Figure 7e). The MYC and S6K were selected as negative controls
since they did not show a significant increase with siRNA-treated cells. While the responses to most
siRNAs were not altered in the pre-treated cells, JUN-specific siRNA showed a significant effect on the
viability of the cells pre-treated with Mcl-1 and Mcl-1/RPS6KA5 combination (emphasized by red
arrows). This was the case for both shock and gradual strategies, and this effect was more significant in
cells pre-treated with Mcl-1/RPS6KA5 siRNA combination. The viability of the cells included in this
experiment showed a similar trend as a response to silencing of other different proteins.

siRNA Response in a Xenograft Model

A xenograft model (human MDA-435 cells in nude mice) was employed to further investigate two
aspects of our in vitro observations; the efficacy and changes in target protein expression with repeat
siRNA injections. We previously reported the efficacy of siRNA therapies in a similar animal model
with intratumoral injections17, but this time we employed a subcutaneous route for siRNA injections in
order not to disrupt the tumor growth directly. Figure 8a summarizes the tumor growth pattern of
treatment (Mcl-1/RPS6KA5 combination, as the most efficacious therapy in vitro) and negative control
groups. Three subcutaneous injections were performed 7 days apart to allow enough time for recovery.
While tumors in the control group showed a continuous growth, the treatment group showed a halting of
tumor growth after each injection and a slight increase in tumor size until the repeat injection, leading no
significant growth during the study period. RT-PCR analysis of mRNA levels of targeted proteins, as
well as JUN (i.e., one protein overexpressed in pre-treated cells) is summarized in Figure 8b. The mRNA
levels was decreased by ~40% (range: 34.6-42.3%) for Mcl-1 and ~45% (range: 43.2-48.8%) for
RPS6KA5 72 hours after each injection, returning to previous levels as the control group after the
recovery period. The JUN expression in Mcl-1/RPS6KA5 siRNA combination treatment was higher than
the control group at all time points, despite some fluctuations during repeat siRNA treatments.

DISCUSSION
Although siRNA delivery has emerged as a promising strategy in cancer therapy, many details
about the silencing process and factors affecting its efficiency remain unknown. The present study was
designed to specifically investigate the effect of siRNA pre-exposure on subsequent response to siRNA
treatments. Three siRNAs employed for this study have promising roles in anti-cancer therapy; (i) Mcl1 is among the anti-apoptotic proteins overexpressed in different cancers22, and promotes survival by
inhibiting mitochondrial cytochrome c release23, (ii) Ribosomal protein S6 kinase family has been linked
to critical proteins involved in cell survival, including NFƙB, MYC, eIF4B, and c-FOS24 and RPS6KA5,
in combination with Mcl-1, showed a significant therapeutic effect in retarding MDA-435 tumors in an

animal model17, and; (iii) KSP is involved in centrosome separation and bipolar spindle assembly, whose
silencing led to suppression of subcutaneous melanomas and ovarian tumors25. Simultaneous delivery of
siRNAs targeting KSP and vascular endothelial growth factor (VEGF) has entered clinical trials, where
the safety and efficacy of this combination is now being investigated26. The diverse nature of the chosen
targets was intended to better extrapolate the significance of our outcomes. Pre-exposure to select
siRNAs was undertaken using two different approaches. The “shock” treatment better mimics the clinical
scenario where the malignant cells were exposed to a relatively high siRNA concentration immediately.
This approach led to a selection of cells that were un-responsive to treatment for a variety of possible
reasons: i) insufficient amount of intracellular siRNA due to low uptake; ii) insufficient silencing due to
high level of mRNA and/or low RISC efficiency, which prevents reaching a critical level of silencing
required for an effect on cell viability; and/or iii) reliance of cells on alternative proteins that minimizes
the effect of silencing. The “gradual” siRNA treatment, on the other hand, affords the cell sufficient time
to adopt and respond to siRNA treatments. Our previous studies indicated that siRNA effect on cell
viability was complete after 72 hours27, so that analysis at 24 hours was employed for the initial cellular
response, while 72-hour analysis represented the response in surviving cells.
The RT-PCR analysis revealed interesting findings about the siRNA pre-treatment. First, the
commercially obtained scrambled siRNA did affect the mRNA expression level of selected targets,
especially KSP, at higher concentrations (>27 nM). The significant drop in cell viability observed with
scrambled siRNA was in past attributed to toxicity of carriers, but it appears that this could be partially
attributed to non-specific silencing by the scrambled siRNA. Secondly, the RT-PCR analysis performed
after 24 hours during gradual siRNA exposure revealed significantly lower response of mRNA levels to
repeated Mcl-1 and RPS6KA5 silencing for most of the exposure steps (but not for KSP). This decrease
in responsiveness was not due to a higher target mRNA levels in pre-treated cells since the 72-hour
analysis in the surviving cells clearly showed a lower mRNA level compared to the naïve cells. Therefore,
we hypothesize that a lower response at the mRNA level might be due to temporary shortness of RISC

complexes in cells pre-exposed to siRNA, which are immediately exposed to a repeat siRNA treatment.
The higher mRNA levels of targeted proteins in surviving cells after the “shock” treatment (compared to
the initial population; Figure 1c) might partially explain the survival of these cells (i.e., cells not
displaying mRNA reduction might have survived better). However, a similar level of Mcl-1 and
RPS6KA5 mRNA in the surviving and original cell population confirmed effective silencing of the target
protein in surviving cells, which raises the possibility of the reliance of these cells on alternative survival
pathways. The same similarity in mRNA levels, however, was not observed for KSP after 24 and 72
hours of treatment. The higher KSP mRNA levels in the surviving cells indicated the possibility of a
lower silencing efficiency in this population, which could also led to better survival of the cells.
One obvious way for cells to adapt to siRNA treatment is by altering the uptake of siRNA
complexes, reminiscent of resistance observed due to up-regulation of drug transporters. The siRNA
uptake studies showed a similar trend in both “shock” and “gradual” siRNA treatments; even though
some groups showed a lower level of siRNA internalization, the difference was relatively minor to rule
out a significant change in cellular internalization of siRNA particles as a cause for any changes in siRNA
response. The confocal imaging also confirmed similar internalization pattern and extent in selected cell
populations. Later time point (72 hours) analysis demonstrated the expected release of internalized
siRNA in a timely manner, which was not found to depend on siRNA pre-treatments. Confocal
microscopy studies, however, indicated heterogeneity in the uptake of siRNA particles, where some cells
had abundant complexes while others did not appear to contain any particles. It is likely that this variation
might have contributed to survival of some cells after siRNA treatment. Flow cytometry analysis also
indicated <30% of cells with minimal (undetectable) siRNA, which confirms our microscopic
observations.
A lower responsiveness in cell viability was observed after repeat siRNA treatment for the Mcl1/RPS6KA5 combination (shock and gradual treatment), but not to Mcl-1 and KSP siRNA treatment.
However, the RT-PCR analysis showed a similar decrease in the mRNA levels of naïve and pre-treated

cells in vitro. These findings indicate that the diminishing therapeutic response (i.e., loss of cell viability)
to repeat treatment did not reflect a lowering silencing efficiency at the mRNA level. It is possible that
overexpression or recruitment of an alternative mediator(s) for survival and proliferation of cells as a
reaction to gradually increasing siRNA silencing. Selection of the cells that rely on alternative mediators
as a result of shock siRNA treatment could be also a realistic possibility. Response in the animal model,
however, was different and there was no indication of diminishing therapeutic response (either in the
tumor growth pattern or target mRNA levels). We recognize the duration of these studies are relatively
short (3 treatments) and longer-term studies might be required to unequivocally confirm this promising
observation.
In order to investigate recruitment of alternative mediators, we analyzed the expression of a select
group of proteins involved in cancer cell survival and proliferation. The selected proteins included
another anti-apoptotic protein (survivin)28, JAK2 and STAT3 as the main effectors of JAK-STAT
pathway29, JUN, FOS, and MYC as downstream effectors of RAS-RAF pathway30, and NFƙB, eIF4, and
S6K as downstream effectors of PI3K-Akt pathway31,32. Interestingly, a significant upregulation in JUN
and STAT3 levels, and to lesser extent in NFƙB and JAK levels, was observed in survived cells after
shock treatment with Mcl-1/RPS6KA5 siRNAs. It is noteworthy that the combination therapy seemed to
have a more significant effect on the selected non-target proteins, which suggests a more likelihood for
activating alternative pathways with silencing two targets simultaneously. The same trend was observed
in gradually exposed cells (except for STAT3, where Mcl-1 silencing alone had a similar effect as the
combinational silencing). The overexpression of non-target proteins in this case was observed after 24
hours, which is likely due to exposure to lower concentrations that were not sufficient for cell kill. Some
reports indicated that cells could become more reliant on overexpressed pro-survival proteins in the face
of drug threat33. We have also recently reported that cells overexpressing Mcl-1 as a result of resistance
development to doxorubicin were more sensitive to Mcl-1 silencing34. Therefore, we investigated the
silencing JUN, STAT3, NFƙB, and JAK (as proteins overexpressed in the pre-treated cells) to evaluate

the over-reliance on a specific mediator. The effect of siRNA silencing on cell viability was significantly
enhanced when up-regulated JUN was targeted. Interestingly, this enhanced response was also more
significant in cells pre-exposed to Mcl-1/RPS6KA5 siRNA combination compared to pre-exposure to
Mcl-1 alone, which correlates with the RT-PCR analysis. The same trend was not observed with other
over-expressed proteins. It seems that while the hypothesis of enhance response to silencing of
overexpressed targets was confirmed in JUN overexpression, the conclusion cannot be generalized at
this stage. Nevertheless, the high sensitivity to up-regulated JUN could provide another avenue for
siRNA therapy if any resistance to therapy was seen in the xenograft model.
We are aware that the described studies might have certain limitations due to the need to maintain
a reasonable scope for publication purposes. Our studies focused on a relatively few siRNA targets and
utilized a particular type of non-viral polymeric carrier (lipid-modified PEI) for siRNA delivery. Our
studies were conducted using a single cell line, MDA-MD-435 cells. Although the origin of this cell line
has been questioned,35 the concept of resistance development affects different types of cancers and our
results will be applicable to any cancer that will benefit from siRNA therapy. Additional studies with
other siRNA targets, different types of non-viral carriers (e.g., lipids or polymers with different types of
chemical modifications) and more cell lines will be needed to fully assess the impact of the reported
observations.
In conclusion, the pre-treatment of cells with siRNA did not seem to significantly alter the extent
of cellular internalization of siRNA-containing particles into target cells. While the decrease in mRNA
levels of targeted proteins might not be as robust as the response in naïve cells as a result of repeated
siRNA treatments (in particular in gradual treatments), the silencing efficiency was nevertheless restored
if a 7-day recovery period was allowed for siRNA treated cells. The mRNA levels of targeted proteins
also returned to original levels in a relatively short period of time (less than 2 weeks) in both “shock”
and “gradual” treatments. Other mediators involved in breast cancer cell survival and proliferation
(notably survivin, JUN, JAK2, NFƙB and STAT3) were altered in siRNA treated cells, but only silencing

JUN led to a heightened loss of viability. In vivo experiments in a xenograft model demonstrated a similar
silencing efficiency at the mRNA level after each repeat dose, with no apparent resistance to the siRNA
therapy. A longer-term investigation of repeated siRNA responses will be important to investigate to
further explore limitations of siRNA therapy.
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FIGURE LEGENDS
Figure 1. Cell response to “shock” siRNA treatment and PCR analysis of targeted proteins. (a) Viability
of MDA-435 cells (as a percentage of the “No Treatment” group) after 72 hours of exposure to siRNA
complexes (54 nM). (b) Viability of naïve and “shock” siRNA treated cells after exposure to different
siRNA concentrations. The designations on the x-axis indicate the siRNA used (C: Control siRNA, M:
Mcl-1, M/R: Mcl-1/RPS6KA5 combination, and K: KSP) and its concentration in nM. Asterisks indicate
significant difference compared to naïve cells. (c) The mRNA level of targeted proteins after 24 and 72
hours exposure to siRNA complexes (54 nM). Asterisks indicate significant difference compared to 24
hours’ time-point. The mRNA level of Mcl-1, RPS6KA5, and KSP in naïve and shock-treated cells after
7 days (d) and 14 days (e) of recovery. (f) The mRNA level of targeted proteins in “shock” siRNA treated
cells (after 7 days of recovery) and naïve cells as the result of 24 hours exposure to siRNA complexes
(54 nM). In all cases, the levels of mRNAs in treated cells were normalized by the mRNA levels in nontreated (NT) cells.
Figure 2. Effect of “shock” siRNA pre-treatment on cellular internalization of siRNA complexes. The
mean fluorescence (a) and percentage of FAM-siRNA positive cells (b) in treated cells compared to naïve
non-treated cells. Asterisk indicates significant difference compared to control siRNA. (c) The confocal
microscopy images after 24 and 72 hours exposure of siRNA complexes to (from left to right in both
time-points) naïve cells, and cells pre-exposed to scrambled, Mcl-1, Mcl-1/RPS6KA5 combination, and
KSP siRNAs. The scale bars represent 20 μm in each picture. Staining for cell nucleus and membrane
are indicated in blue and red, respectively.
Figure 3. Cell response to gradual siRNA treatments. (a) Viability of MDA-435 cells after 72 hours (as
percentage of “No Treatment” group) of exposure to siRNA complexes. At 18 nM siRNA treatment, the
cells were already pre-treated with 9 nM of siRNA targeting Mcl-1, Mcl-1/RPS6KA5 combination and
KSP (except naïve cells). At 27 nM siRNA treatment, the cells were already pre-treated with 9 and 18

nM of siRNA targeting Mcl-1, Mcl-1/RPS6KA5 combination and KSP (except naïve cells). (b) Viability
of naïve and “gradual” siRNA treated cells after exposure to different siRNA concentrations. The
“gradual” treated cells were allowed to recover for 7 days (from the last exposure to 27 nM specific
siRNA treatment) before the siRNA treatment. The designations on the x-axis indicate the siRNA used
(C: Control siRNA, M: Mcl-1, M/R: Mcl-1/RPS6KA5 combination, and K: KSP) and its concentration
in nM. Asterisks indicate significant difference compared to naïve cells.
Figure 4. RT-PCR analysis of “gradual” siRNA treated cells for silencing efficiency. The mRNA levels
of targeted proteins after 24 (left panels) and 72 hours (right panels) of siRNA treatment with gradually
increasing concentrations (9, 18 and 27 nM, followed by a repeat 27 nM treatment), as indicated on
individual figures. In all cases, the levels of mRNAs in siRNA treated cells were normalized by the
mRNA levels in non-treated (NT) cells. Asterisks indicate significant difference compared to naïve cells.
Figure 5. RT-PCR analysis of cells recovered from “gradual” siRNA treatment for silencing efficiency.
The mRNA levels of Mcl-1, RPS6KA5 and KSP in naïve and siRNA-treated cells after 7 (a) and 14 days
(b) of recovery. Asterisks indicates significant difference compared to control siRNA. (c) The mRNA
levels of targeted proteins in “gradual” siRNA treated cells (7 days of recovery) and naïve cells as the
result of 24 hours exposure to siRNA complexes (54 nM).
Figure 6. Effect of “gradual” siRNA pre-treatment on cellular internalization of siRNA complexes. The
mean fluorescence (a) and percentage of FAM-siRNA positive cells (b) in treated cells compared to naïve
non-treated cells. (c) The confocal microscopy images after 24 and 72 hours exposure of siRNA
complexes to (from left to right in both time-points) naïve cells, and cells pre-exposed to scrambled, Mcl1, Mcl-1/RPS6KA5 combination, and KSP siRNAs. The scale bars represent 20 μm in each picture.
Staining for cell nucleus and membrane are indicated in blue and red, respectively. Asterisk indicates
significant difference compared to control siRNA.

Figure 7. A. RT-PCR analysis of non-targeted proteins in “shock” (a and c) and “gradual” (b and d)
siRNA treated cells. The mRNA level of selected proteins were analyzed after 24 hours (a and b) and 72
hours (c and d) of treatment with siRNAs against Mcl-1 and Mcl-1/RPS6KA5 combination. The mRNA
levels of indicated proteins in siRNA treated cells were normalized against un-treated cells. Asterisks
indicate a significant overexpression compared to no treatment. B. Cell viabilities of “shock” (a) and
“gradual” (b) siRNA pre-treated cells after silencing for JAK, JUN, NF-B, STAT3, MYC and S6K.
The resultant cell viabilities were normalized with respect to the naïve cells. Red arrows indicate the
significant increase in responsiveness of cells pre-exposed to Mcl-1 (SM and GM) or Mcl-1 and
RPS6KA5 combination (SM/R and GM/R) to JUN silencing.
Figure 8. siRNA therapy in a xenograft model with a negative control siRNA and Mcl-1/RPS6KA5
siRNA combination. (a) Changes in tumor volumes treated with control siRNA and Mcl-1/RPS6KA5
siRNA combination. The siRNA injection was undertaken 3 times with 7 day intervals in between the
injections (indicated as arrows). n = 15, 9 and 3 for data points in week-1, week-2 and week-3,
respectively. (b) RT-PCR analysis of tumor cells for the two targeted proteins (Mcl-1 and RPS6KA5)
and the non-targeted JUN. The tumors were recovered either 2 or 7 days after siRNA injection for RTPCR analysis. The levels of the indicated mRNAs were normalized against the tumors treated with
control siRNA. n = 3 at each data point.

